8-K/A: Vyome Holdings Corrects Merger Pro Forma Financials

Vyome Holdings, Inc. filed an amendment to correct calculations in its unaudited pro forma condensed combined financial statements related to its merger with ReShape and concurrent financing.

Summary

• An amendment was filed to correct calculations in the unaudited pro forma condensed combined financial statements for the merger of Vyome into ReShape.
• The merger closed on August 14, 2025, with Vyome surviving as a subsidiary of ReShape, and Vyome determined to be the accounting acquirer.
• ReShape sold substantially all of its assets (excluding cash) and transferred liabilities to Biorad for approximately $1.6 million in cash.
• Holders of Vyome shares, together with holders of Vyome securities convertible into Vyome shares, are expected to own 91.62% of the outstanding ReShape shares on a fully-diluted basis immediately after the Effective Time.
• A Concurrent Financing of approximately $7.30 million in securities was agreed upon, of which approximately $660,000 was received in the form of bridge notes through the Effective Time.
• The pro forma combined entity reported a net loss of $522 thousand and revenue of $249 thousand for the six months ended June 30, 2025.
• Pro forma total assets were $6,952 thousand and total liabilities were $2,160 thousand as of June 30, 2025.

Sentiment

Score: 4

Explanation: While the merger and capital raise provide strategic benefits and funding, the pro forma financials show a net loss for the combined entity, and the asset sale indicates a divestiture of ReShape's prior operations. The amendment itself is a correction, which can be seen as a minor negative for accuracy.

Positives

• The strategic merger with Vyome as the accounting acquirer provides a new direction and market access for the combined entity.
• The merger successfully closed on August 14, 2025, providing certainty to the transaction.
• A Concurrent Financing of approximately $7.30 million was secured, strengthening the combined company's capital position.
• ReShape's Series C Preferred Stock liquidation preference was significantly reduced from $26.2 million to a lower amount (greater of $1 million, 20% of asset sale price, or net cash excess), reducing future obligations.

Negatives

• The pro forma combined entity reported a net loss of $522 thousand for the six months ended June 30, 2025.
• ReShape divested substantially all of its operating assets, indicating a shift away from its previous core business.
• ReShape incurred significant transaction costs, employee-related expenses (PTO, severance), and D&O tail insurance costs related to the merger and asset sale.
• The Concurrent Financing involves a 30% discount to the agreed-upon valuation for the combined company's common stock, which could be dilutive to existing shareholders.

Risks

• The market price of ReShape Shares is subject to general price fluctuations and has experienced historical volatility, which may continue.
• There is a potential for additional differences between ReShape's and Vyome's accounting policies, which, when conformed, could materially impact the combined consolidated financial statements.
• Certain Vyome shares and Vyome India shares are subject to put-call option agreements, which could introduce future complexities or potential cash outflows for the combined company.
• The unaudited pro forma financial information is for illustrative purposes only and is not necessarily indicative of the combined company's future financial position or operating results.

Future Outlook

The unaudited pro forma condensed combined financial statements are for illustrative purposes only and are not necessarily indicative of the consolidated financial position or results of operations that would have been realized had the Merger occurred as of the dates indicated, nor are they meant to be indicative of any future consolidated financial position or future results of operations that the Combined Company will experience.

Management Comments

• Management believes the pro forma adjustments are based on reasonable assumptions and currently available data.
• Vyome management is expected to hold all key positions in the management of the combined company.
• Vyome management assessed ReShape's accounting policies to be similar in all material respects to Vyome's.

Industry Context

This merger and asset sale represent a strategic restructuring, common in the biotechnology or medical device sectors, where companies divest non-core assets to focus on new growth areas or integrate with a more dominant entity. The transaction positions Vyome, as the accounting acquirer, to leverage ReShape's public listing while shedding ReShape's previous operating liabilities, aligning with a trend of 'reverse mergers' for market access.

Corporate Governance

Related Party Transactions

• Biorad, which acquired ReShape's assets, was previously party to an exclusive license agreement with ReShape for its Obalon Gastric Balloon System.
• Promissory notes issued by Vyome to ReShape in the principal amount of $600,000 were outstanding.
• Certain investors in the Concurrent Financing are existing Vyome stockholders, which will further decrease the actual ownership percentage of ReShape stockholders.

Stakeholder Impact

• **Shareholders (Vyome):** Will become majority owners (91.62%) of the combined public company, gaining market access and control.
• **Shareholders (ReShape):** Will experience significant dilution, with their ownership decreasing due to Vyome's majority stake and the Concurrent Financing. Their Series C Preferred Stock liquidation preference was reduced.
• **Employees (ReShape):** Incurred severance, termination, and PTO payments due to the asset sale and merger, indicating job losses or changes.
• **Customers (ReShape/Biorad):** ReShape's Obalon Gastric Balloon System business will now be managed by Biorad.
• **Creditors (Vyome):** Convertible debt and bridge notes will convert into common shares, altering their position from creditors to equity holders.

Next Steps

• Conversion of Vyome's convertible debt, preferred stock, and bridge financing into common shares prior to the merger.
• Determination of the Exchange Ratio at least 10 calendar days prior to the ReShape Special Meeting.
• Execution and delivery of registration rights agreements for Concurrent Financing investors.

Key Dates

Recommendation

The merger with Vyome and the associated capital raise provide a new strategic direction and financial injection for the combined entity. However, the pro forma financials show a net loss, and the significant restructuring of ReShape's original business introduces uncertainty. While the long-term potential of the new combined entity under Vyome's leadership could be positive, the immediate financial performance and the dilutive nature of the financing warrant a cautious 'hold' until more operational results are available.

Keywords

Vyome Holdings, ReShape, Merger, Pro Forma Financials, Asset Sale, Concurrent Financing, Reverse Recapitalization, Corporate Governance, Nasdaq, Biotechnology